m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG01430)
Name
STO609
Synonyms
STO-609; STO 609
    Click to Show/Hide
Status
Investigative
Structure
Formula
C19H10N2O3
InChI
1S/C19H10N2O3/c22-18-13-5-3-4-10-11(19(23)24)8-9-12(16(10)13)17-20-14-6-1-2-7-15(14)21(17)18/h1-9H,(H,23,24)
InChIKey
MYKOWOGZBMOVBJ-UHFFFAOYSA-N
PubChem CID
3467590
TTD Drug ID
D0HZ8U
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Calmodulin-dependent kinase II (CAMKK2)
Methyltransferase-like 14 (METTL14)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Calmodulin-dependent kinase II (CAMKK2) is a therapeutic target for STO609. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of STO609 through regulating the expression of Calmodulin-dependent kinase II (CAMKK2). [1], [2]
RNA demethylase ALKBH5 (ALKBH5)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Calmodulin-dependent kinase II (CAMKK2) is a therapeutic target for STO609. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of STO609 through regulating the expression of Calmodulin-dependent kinase II (CAMKK2). [1], [2]
References
Ref 1 m(6)A mRNA methylation regulates testosterone synthesis through modulating autophagy in Leydig cells. Autophagy. 2021 Feb;17(2):457-475. doi: 10.1080/15548627.2020.1720431. Epub 2020 Jan 31.
Ref 2 7,8-dichloro-1-oxo-Beta-carbolines as a versatile scaffold for the development of potent and selective kinase inhibitors with unusual binding modes. J Med Chem. 2012 Jan 12;55(1):403-13. doi: 10.1021/jm201286z. Epub 2012 Jan 3.